Chronic myelogenous leukemia epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
CML is more common in males than in females with male-to-female ratio varying between 1.2 and 1.7 in different studies [8, 20, 27]. The gender difference in incidence is less prominent in younger age groups.PMID:25814090 | CML is more common in males than in females with male-to-female ratio varying between 1.2 and 1.7 in different studies [8, 20, 27]. The gender difference in incidence is less prominent in younger age groups.PMID:25814090 | ||
Chronic myelogenous leukemia accounts for 15% of adult leukemias, has an incidence of 1 to 2 cases per 100000 population, and has a male-to-female ratio of 1.3 to 1. Incidence increases with age. The median age at presentation is 45 to 55 years, although some series report a median age of up to 67 years (4, 5). This is important when therapeutic options are being considered. Stem-cell transplantation is associated with a high procedure-related mortality rate, and interferona therapy produces a higher incidence of neurotoxicity and other side effects in older patients. It also emphasizes the need to continue investigating better strategies for patients who may not benefit as much as younger patients from recent treatment discoveries. | |||
PMID: | |||
: 10428738 | |||
==Epidemiology== | ==Epidemiology== | ||
Revision as of 13:50, 13 May 2018
|
Chronic myelogenous leukemia Microchapters |
|
Differentiating Chronic myelogenous leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic myelogenous leukemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Chronic myelogenous leukemia epidemiology and demographics |
|
FDA on Chronic myelogenous leukemia epidemiology and demographics |
|
CDC on Chronic myelogenous leukemia epidemiology and demographics |
|
Chronic myelogenous leukemia epidemiology and demographics in the news |
|
Blogs on Chronic myelogenous leukemia epidemiology and demographics |
|
Directions to Hospitals Treating Chronic myelogenous leukemia |
|
Risk calculators and risk factors for Chronic myelogenous leukemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults, and accounts for 15%
of newly diagnosed cases of leukemia in adults. PMID:24729196
Its incidence is 2 per 100 000/year. The peak age for the disease is 50 to 55.PMID:20221270
Published data on the annual incidence of CML varies from as low as 0.4/100,000 persons in some non-Western countries to 1.75/100,000 in the USA [7, 8, 9, 15, 16, 17, 18, 19]. As the incidence of CML increases by age, some of these variations are due to significant differences in the age distributions of the investigated populations (e.g. Western vs several non-Western countries). However, also figures on age-adjusted incidence vary considerably (0.7–1.8/100,000) between different studies.
The incidence in CML increases by age, at least up to 75–80 years (Fig. 1). In Europe, the median age at diagnosis of CML, as estimated from population-based registries, is 57–60 years (Table 1) [9, 20]. Importantly, this is about 10 years above the median age typically seen in clinical trials [19]. In children, CML is a very rare disease with an incidence of 0.6–1.2 million children/year [26].
CML is more common in males than in females with male-to-female ratio varying between 1.2 and 1.7 in different studies [8, 20, 27]. The gender difference in incidence is less prominent in younger age groups.PMID:25814090
Chronic myelogenous leukemia accounts for 15% of adult leukemias, has an incidence of 1 to 2 cases per 100000 population, and has a male-to-female ratio of 1.3 to 1. Incidence increases with age. The median age at presentation is 45 to 55 years, although some series report a median age of up to 67 years (4, 5). This is important when therapeutic options are being considered. Stem-cell transplantation is associated with a high procedure-related mortality rate, and interferona therapy produces a higher incidence of neurotoxicity and other side effects in older patients. It also emphasizes the need to continue investigating better strategies for patients who may not benefit as much as younger patients from recent treatment discoveries.
PMID:
- 10428738
Epidemiology
Incidence
Age
Gender
References
- ↑ 1.0 1.1 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.